Revenue: As of FY2026 Q2, the actual value is USD 7.899 M.

EPS: As of FY2026 Q2, the actual value is USD -0.52.

EBIT: As of FY2026 Q2, the actual value is USD -8.377 M.

Net Revenue

BioStem Technologies, Inc. reported net revenue of $7.9 million for the second quarter of 2026, representing a 29% sequential growth from $6.1 million in the first quarter of 2026. This compares to $11.0 million in the second quarter of 2025. Revenue for the second quarter was primarily driven by Neox® and Clarix® product sales.

Segment Revenue

Hospital revenue reached $6.7 million in the second quarter of 2026, an increase from $5.7 million in the first quarter of 2026. Physician office revenue was $1.1 million in the second quarter, up from $0.8 million in the first quarter of 2026.

Gross Profit and Gross Margin

Gross profit for the second quarter of 2026 was $4.8 million, representing a gross margin of 61%. This is an increase from $3.8 million in gross profit with a 61% gross margin in the first quarter of 2026. In the second quarter of 2025, gross profit was $10.3 million with a gross margin of 94%. The sequential increase in gross profit was due to higher revenue, while the gross margin remained flat sequentially.

Operating Expenses

Total operating expenses were $13.2 million in the second quarter of 2026, compared to $12.6 million in the first quarter of 2026 and $10.2 million in the second quarter of 2025. The sequential increase was mainly due to the expanding commercial team and infrastructure, partially offset by lower clinical trial and administrative spending.

GAAP Net Loss

BioStem Technologies, Inc. reported a GAAP net loss of - $9.0 million, or - $0.52 per share, for the second quarter of 2026. This contrasts with a net income of $10,613, or $0.00 per share, in the second quarter of 2025.

Adjusted EBITDA Loss

Adjusted EBITDA loss was - $4.6 million for the second quarter of 2026, compared to an Adjusted EBITDA of $2.5 million in the second quarter of 2025.

Cash and Cash Equivalents

As of June 30, 2026, cash and cash equivalents totaled $7.0 million. This is a decrease from $13.7 million at the end of the first quarter of 2026.

Cash Flow from Operations

Cash used in operations during the second quarter of 2026 was $5.5 million.

Unique Financial Events

During the second quarter, BioStem Technologies, Inc. closed a $2.5 million private financing. The company also resolved $5.3 million in outstanding debt through a $3.5 million cash payment and the issuance of a $1.0 million promissory note.

2026 Financial Outlook

BioStem Technologies, Inc. has raised its full-year 2026 revenue guidance to a range of $26 million to $29 million. This represents an increase from its prior guidance of $25 million to $29 million.